New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention.

ABSTRACT:

Purpose of review

The primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) relies on optimizing cardiovascular health and appropriate pharmacotherapy, a mainstay of which is low-density lipoprotein-cholesterol (LDL-C) lowering. Typically, statin therapy remains the first line approach. Advances in technology and understanding of lipid metabolism have facilitated the development of several novel therapeutic targets and medications within the last decade. This review focuses on medications recently approved by the U.S. Food and Drug Administration (FDA) for the reduction of LDL-C and ASCVD risk, as well as new therapies in the pipeline.

Recent findings

Novel lipid therapies aim to lower risk of ASCVD by targeting reduction of atherogenic compounds

SUBMITTER: Gaine SP 

PROVIDER: S-EPMC9543364 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature